与PTK2相关的基因特征可以预测IPF的预后
Anlin Feng1, Yesenia Moreno Caro2, Colin Gardner2
1Center for Translational Science, and Department of Environmental Health, Florida International University, Port St. Lucie, FL, 36987, USA.
Respiratory research
|December 5, 2023
概括
一个新的PTK2分子签名有效地预测了异常性肺纤维化 (IPF) 患者的预后. 这种来自PTK2关联基因的特征识别了生存率降低的高风险个体,为IPF提供了一种新的预后生物标志物.
科学领域:
- 肺部病理学 肺部病理学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 异形性肺纤维化 (IPF) 是一种致命的肺病,预后工具有限.
- 由PTK2基因调节的焦粘合激酶 (FAK) 参与了IPF的发病.
- 在纤维细胞中的FAK激活表明其作为IPF治疗标或生物标记物的潜力.
研究的目的:
- 利用血液中的PTK2-关联基因开发基因特征,以预测IPF预后.
- 评估PTK2及其相关基因在IPF患者的预后价值.
主要方法:
- 来自IPF患者血液样本的PTK2相关基因和微阵列数据的分析.
- 开发使用考克斯回归的11基因PTK2分子特征和风险评分系统.
- 在发现和验证队伍中验证签名.
主要成果:
- 在IPF肺组织中观察到升高的PTK2水平,但仅血液PTK2无法预测预后.
- 11基因PTK2分子特征将患者分为高风险和低风险组.
- 高风险患者的生存率显著下降.
- 这种特征与免疫路径和免疫细胞激活水平相关.
结论:
- PTK2 是一个与IPF相关的分子标.
- PTK2分子签名作为IPF的强大和验证的预后生物标志物.
- 这种签名可能有助于分层患者和指导临床管理.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K